ClinicalTrials.gg
Status unknownNCT05202899Updated Mar 9, 2022

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

A Phase 4 interventional study of sugammadex in Brain Tumors, sponsored by Guangzhou General Hospital of Guangzhou Military Command. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-09.

Sponsored by Guangzhou General Hospital of Guangzhou Military Command · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Sep 2020, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies in Brain Neoplasms with a site in China — 73 open to participants now, 84 under way, 7 of them phase 3. Brain Neoplasms · China.

Planned enrollment
93rd of 143
40 · median 60
Started
2020
with 15 others
Phase 4
3 of 180
none open now
Registered
91st of 180
by date

Among the 180 studies in Brain Neoplasms with a site in China, this one is the 93rd largest by planned enrollment of the 143 interventional ones that give a count, is one of 16 that started in 2020, is one of 3 in phase 4, and was the 91st registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

73 of the 180 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Brain Neoplasms with a site in China, or all of them as a file.
02

Study summary

Effect of sugammadex for reversal of rocuronium-induced neuromuscular block on Perioperative Management of awake Craniotomy

03

Conditions studied

  • Brain Tumors

Browse trials for

Keywords

  • sugammadex、awake craniotomy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-45 years old (BMI)≥ 18.5-23.9 kg/m2, I \~II.

Exclusion criteria

Exclusion Criteria:

  • Suffering from a mental illness or preoperative communication disorder, patients with claustrophobia, breathing, circulation, neuromuscular system and kidney, and other important viscera function disorder, pregnant or lactating women, a history of malignant hyperthermia, the history of drug allergy in the process of general anesthesia and recent may not used to the interaction between rocuronium, vecuronium bromide reacts drugs (such as aminoglycoside antibiotics, Anticonvulsant, magnesium).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Sugammadex Group

    rocuronium-induced general anesthesia,use of sugammadex antagonism

    Drug: sugammadex

  • No intervention
    Control Group

    general anesthesia without rocuronium

Interventions

  • The use of sugammadex

    Also known as: Bridion, Org 25969

06

What researchers measure

Primary outcomes

  1. awake time

    The time between asleep and awake

    Time frame: 10-30 minutes

07

Study locations

1 of 1 sites recruiting
  • Guangzhou Military Region General Hospital, Department of Anesthesiology
    Guangzhou, Guangdong 510010, China
    Recruiting
    • Cong Wei Luo · Contact903740316@qq.com · 18819457246
    • Cong Wei Luo, 86 · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Feb 2022, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Jan 24, 2022
StartActual
Sep 1, 2020
Primary completionEst.
Feb 28, 2022
CompletionEst.
May 31, 2022
Last update
Mar 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05202899
Lead sponsor
Guangzhou General Hospital of Guangzhou Military Command
Responsible party
bo xu (Clinical Professor, Guangzhou General Hospital of Guangzhou Military Command) — Principal investigator
First posted
Jan 24, 2022
Start date
Sep 1, 2020
Primary completion
Feb 28, 2022 (estimated)
Completion
May 31, 2022 (estimated)
Last update
Mar 9, 2022

Study contacts

bo xu, DR
Contact
xubo333@hotmail.com
88653387 ext. 020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sugammadex

Start the discussion